To reach the next value inflection
LicenseRx asset brief
LRRK2 Inhibitors: Novel Treatment for Intestinal Bowel Disorders
Probability of Success
16% · grade C · Medium data confidence
Model PoS 16% (grade C, medium data confidence). Strongest signals: IP position, Indication pull. Biggest drag: Translational evidence.
Data maturity (22%)
41
Early / Discovery; human data.
IP position (16%)
88
Issued/granted patent on record.
Modality feasibility (14%)
55
Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.
Indication pull (14%)
76
Ophthalmology, Oncology -- active buyer appetite.
Competitive whitespace (12%)
78
Under-served segment; crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
54
Public evidence mentions: human.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →